[
  {
    "question": "Patient with headache lasting less than 1 min occur 40 times a day associated with lacrimation and eye injection what is the treatment (not so sure about it)",
    "option_a": "Indomethacin",
    "option_b": "Lamotrigine",
    "option_c": "Carbamazepine",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "This headache description \u2013 very short duration (<1 minute), high frequency (around 40 attacks per day), and associated with lacrimation and eye injection \u2013 is most consistent with a short-lasting unilateral neuralgiform headache with autonomival features, such as SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing). SUNCT is part of the trigeminal autonomic cephalalgias. The pathophysiology likely involves abnormal activation of the trigeminal nerve and the parasympathetic system, with hypothalamic involvement. Lamotrigine is thought to stabilize neuronal membranes by modulating voltage\u2010gated sodium channels, thereby reducing the hyperexcitability that triggers these paroxysmal attacks. Patients with SUNCT typically experience multiple very brief, excruciating attacks per day along with ipsilateral autonomic signs (e.g. lacrimation, conjunctival injection). This pattern differentiates SUNCT from other headache disorders such as trigeminal neuralgia or cluster headache, which differ in trigger, duration, and associated features. Diagnosis is clinical. Differential diagnoses include: (1) Trigeminal Neuralgia \u2013 which usually lacks prominent autonomic symptoms; (2) Cluster Headache \u2013 typically longer-lasting (15\u2013180 minutes) and less frequent; (3) Paroxysmal Hemicrania \u2013 attacks last 2\u201330 minutes and are exquisitely indomethacin responsive. Evaluation is based on attack duration, frequency, associated symptoms, and response to specific treatments. The first\u2010line preventive treatment for SUNCT is lamotrigine. If lamotrigine is ineffective or not tolerated, alternatives such as topiramate or gabapentin may be considered. In pregnant or lactating patients, lamotrigine is relatively favored over many other agents due to its more favorable safety profile, though careful risk-benefit assessment is still required. Option A (Indomethacin) is the treatment of choice for paroxysmal hemicrania, which typically has longer attack durations. Option B (Lamotrigine) is correct for SUNCT. Option C (Carbamazepine) is mainly used in trigeminal neuralgia but does not address the autonomic features seen in SUNCT. 1. SUNCT is characterized by very brief but frequent attacks with significant autonomic signs. 2. Lamotrigine is considered the treatment of choice. 3. Differentiation from similar cephalgias is largely based on attack duration and response to specific drugs. Recent studies and expert consensus continue to support lamotrigine as the first-line treatment for SUNCT, validating its use in clinical practice despite the limited size of controlled trials in this rare disorder. Ongoing research is focused on understanding the central mechanisms to develop even more targeted therapies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of migraine came with nausea and vomiting, LFT normal, with high amylase & lipase levels. Which of the following preventive Rx of migraine is known to cause this side effect?",
    "option_a": "Valproate",
    "option_b": "Propranolol",
    "option_c": "Topiramate",
    "option_d": "Amitriptyline",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Migraine prophylaxis involves several medications that carry specific side effect profiles. In this case, a patient with migraine presents with nausea, vomiting, and laboratory findings of elevated amylase and lipase, which is indicative of pancreatitis. Among the migraine preventive options, valproate is known to potentially cause pancreatitis. Valproate is metabolized in the liver and can generate toxic intermediates that may injure the pancreas, leading to pancreatitis even in the absence of overt liver function test abnormalities. Although hepatotoxicity is more commonly discussed, pancreatitis is a recognized and serious adverse effect of valproate. The clinical picture of gastrointestinal upset with elevated pancreatic enzymes in a patient on migraine prophylaxis should raise suspicion for drug-induced pancreatitis. Recognizing this association is crucial because valproate, besides causing weight gain and hair loss, is also implicated in pancreatic injury, which can be severe. When a patient on valproate presents with symptoms suggestive of pancreatitis, the differential includes gallstone pancreatitis, alcohol-induced pancreatitis, and pancreatitis due to other medications. The work-up includes a thorough history, abdominal imaging (like ultrasound or CT scan), and careful review of medication history, ensuring that other causes are excluded. The management involves the immediate cessation of valproate and supportive care for pancreatitis, including intravenous fluids, pain control, and monitoring for complications. In the context of migraine prophylaxis, alternative agents such as beta-blockers or topiramate should be considered. Notably, valproate is contraindicated in pregnancy due to its teratogenicity and should be avoided in women of childbearing potential or managed with extreme caution during lactation. Option A (Valproate) is correct as it is known to cause pancreatitis. Option B (Propranolol) does not have a known significant association with pancreatitis. Option C (Topiramate) is more often associated with weight loss and kidney stones, not pancreatitis. Option D (Amitriptyline) is known for anticholinergic effects but not for causing pancreatic enzyme elevation. 1. Always monitor patients on valproate for signs of pancreatitis, even if liver enzymes are normal. 2. Valproate-induced pancreatitis, while rare, is a serious adverse effect that necessitates prompt recognition and drug discontinuation. 3. In women of childbearing age or those who are pregnant/lactating, valproate is generally avoided due to additional teratogenic risks. Updated guidelines and recent literature stress caution when using valproate, particularly among women of childbearing potential, and advise routine monitoring for signs of pancreatic toxicity. The evidence reinforces its association with pancreatitis albeit infrequently, prompting clinicians to consider alternative prophylactic agents when appropriate.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "What\u2019s the mechanism of action of Botox in migraine headache?",
    "option_a": "Serotonin agonist",
    "option_b": "Serotonin reuptake inhibitors",
    "option_c": "Monoamine inhibitor",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "Botox (onabotulinumtoxinA) is approved for the prophylactic treatment of chronic migraine. Its mechanism of action in migraine is distinct from that of serotonergic agents. The options provided (serotonin agonist, serotonin reuptake inhibitors, monoamine inhibitor) are not relevant to Botox's mechanism. Botulinum toxin type A works by cleaving the SNARE protein SNAP-25, which is essential for the exocytosis of neurotransmitters. This inhibition suppresses the peripheral release of neuropeptides (such as CGRP, substance P, and glutamate) that play a key role in pain transmission and neurogenic inflammation in chronic migraine. By reducing the release of these pain mediators, Botox decreases the peripheral sensitization of the trigeminovascular system and, consequently, the frequency and severity of migraine attacks. This mechanism is supported by the results of large clinical trials such as the PREEMPT studies. This question pertains to the mechanism of action rather than differential diagnosis. In clinical practice, the response to Botox is evaluated based on reduction in headache frequency and improvement in quality of life for patients with chronic migraine. In managing chronic migraine, Botox is typically reserved for patients who have failed or not tolerated multiple first-line prophylactic therapies. In pregnancy, Botox is classified as Category C (animal studies have shown an adverse effect but there are no adequate human studies), so its use should be carefully considered only if the benefits clearly outweigh the risks. Lactating women should also be counseled regarding potential risks, although systemic absorption is minimal. Option A (Serotonin agonist), Option B (Serotonin reuptake inhibitors), and Option C (Monoamine inhibitor) are incorrect as they do not describe the mechanism by which Botox works. Option D, interpreted as 'none of the above' or representing the actual mechanism (i.e., inhibition of neurotransmitter release via SNARE complex cleavage), is correct. 1. Botox\u2019s efficacy in chronic migraine is attributed to its inhibition of neurotransmitter release rather than direct modulation of serotonin pathways. 2. The PREEMPT trials provide robust evidence for the use of Botox in chronic migraine sufferers. 3. Always consider the risk\u2013benefit profile in special populations such as pregnant or lactating women. Recent research and guideline updates consistently support Botox\u2019s role in chronic migraine prophylaxis, emphasizing its unique mechanism of blocking neurotransmitter release. Ongoing studies continue to refine its optimal dosing and placement strategies to maximize its clinical benefits.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "HC ttt (case with continues headache with episodes of more intense one)",
    "option_a": "(Indomethacin) is correct as it is the established treatment for hemicrania continua. Option B (Valproic acid) is effective for migraine prophylaxis but not for hemicrania continua. Option C (Lamotrigine) and Option D (Naproxen) lack evidence for efficacy in hemicrania continua and do not exhibit the same dramatic response as indomethacin.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "Hemicrania continua is a primary headache disorder characterized by a continuous unilateral headache with superimposed exacerbations. Its hallmark is an absolute and dramatic response to indomethacin, which is considered both diagnostic and therapeutic. The underlying mechanism is not fully elucidated but likely involves abnormalities in central pain processing and hypothalamic dysfunction, leading to activation of trigeminal nociceptive pathways. The robust effect of indomethacin is thought to be due to its potent cyclooxygenase inhibition, reducing prostaglandin-mediated inflammation. Clinically, hemicrania continua presents as a persistent one-sided headache with episodic flares of more intense pain. The complete and rapid resolution of symptoms on indomethacin therapy distinguishes it from other chronic headache disorders. The diagnosis is primarily clinical, relying on the patient\u2019s history and a positive indomethacin trial. Differential diagnoses include chronic migraine and other trigeminal autonomic cephalalgias like cluster headache, which do not exhibit an absolute response to indomethacin. Indomethacin is the first-line and gold standard treatment for hemicrania continua. The dosing is typically titrated to achieve complete headache suppression. In pregnant patients, indomethacin use is generally avoided in the third trimester due to risks such as premature closure of the ductus arteriosus; caution is also advised during lactation with consideration of alternate therapies if necessary. Option A (Indomethacin) is correct as it is the established treatment for hemicrania continua. Option B (Valproic acid) is effective for migraine prophylaxis but not for hemicrania continua. Option C (Lamotrigine) and Option D (Naproxen) lack evidence for efficacy in hemicrania continua and do not exhibit the same dramatic response as indomethacin. 1. Hemicrania continua is uniquely and completely responsive to indomethacin\u2014a response that is pathognomonic. 2. A diagnostic indomethacin trial is essential when hemicrania continua is suspected. 3. Long-term NSAID use mandates monitoring for potential adverse effects. Recent guideline updates and clinical reviews reaffirm indomethacin as the treatment of choice for hemicrania continua, highlighting the drug\u2019s diagnostic importance and prompting ongoing research into alternative therapies for patients intolerant of indomethacin.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Obese female with BA, for migraine prophylaxis",
    "option_a": "(Beta",
    "option_b": "(Valproic acid) is avoided because of weight gain and teratogenicity. Option C (Amitriptyline) is less favorable given its side effects of sedation and weight gain. Option D (Topiramate) is ideal as it helps with weight loss and poses no risk for asthma exacerbation.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "T",
    "subspecialty": "Headache",
    "explanation": "In migraine prophylaxis, choosing the appropriate agent is influenced by comorbid conditions. In this case, the patient is an obese female with bronchial asthma. Effective migraine prophylactics include beta\u2010blockers, anticonvulsants, and tricyclic antidepressants. However, the side effect profile and contraindications must be considered, making topiramate, which is associated with weight loss and is safe in asthma, the preferred choice. Migraines are thought to result from neuronal hyperexcitability and abnormal brainstem activation. Prophylactic agents work by modulating neurotransmitters and ion channels; for example, topiramate blocks voltage-dependent sodium channels, enhances GABA activity, and antagonizes glutamate receptors. Its ability to induce weight loss is due to appetite suppression and altered energy expenditure, making it beneficial in obese patients. An obese female with a history of bronchial asthma is at risk if given beta-blockers (which can provoke bronchospasm) or medications that cause weight gain (like valproic acid or amitriptyline). Topiramate not only helps reduce migraine frequency but also may assist with weight management, fitting this patient's clinical profile. Before initiating prophylaxis, it is essential to confirm the migraine diagnosis, assess frequency and severity, and thoroughly review comorbidities. Differential diagnoses such as tension-type headaches or secondary causes of headache should be ruled out based on clinical history and examination. According to current guidelines, topiramate is a first-line option in patients where weight gain is undesirable and comorbidities like asthma preclude the use of beta-blockers. When initiating topiramate, start at a low dose and gradually titrate to minimize side effects such as cognitive slowing or paresthesias. In women of childbearing age or those planning pregnancy, discussion regarding its teratogenic potential is crucial, and alternative agents might be considered if pregnancy is imminent. Option A (Beta-blockers) is unsuitable due to risk of bronchospasm in asthma. Option B (Valproic acid) is avoided because of weight gain and teratogenicity. Option C (Amitriptyline) is less favorable given its side effects of sedation and weight gain. Option D (Topiramate) is ideal as it helps with weight loss and poses no risk for asthma exacerbation. 1) Topiramate can offer dual benefits in migraine prophylaxis and weight loss, making it ideal for obese patients. 2) Beta-blockers should be avoided in patients with bronchial asthma due to potential bronchoconstriction. 3) Always tailor migraine prophylaxis to the patient\u2019s comorbid conditions. Recent clinical guidelines and studies (e.g., from the American Headache Society) support the use of topiramate in patients with these specific comorbidities. Its efficacy and safety profile in migraine prophylaxis, particularly among patients who are obese, has been well documented in the literature.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Female with migraine once a month, brain MRI showed 1 small white matter lesion in each hemisphere, what to do next:",
    "option_a": "(CTA) is unnecessary because there are no signs of vascular pathology. Option C (Methylprednisolone) is inappropriate without evidence of an acute demyelinating event. Option D (IVIG) is not indicated for benign incidental findings. Option B (Reassurance) is correct as these lesions are common and benign in migraine.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Incidental white matter lesions (WMLs) are frequently observed in patients with migraine and are often benign. In a patient with infrequent migraine attacks and no other neurological deficits, these lesions are typically considered an epiphenomenon rather than a sign of progressive neurological disease. The pathogenesis of WMLs in migraine is thought to involve small-vessel ischemic changes, possibly due to microvascular dysregulation or transient vasospasm. These lesions are usually nonspecific and do not indicate demyelinating conditions such as multiple sclerosis. In patients with infrequent migraines and no additional neurological symptoms, a few small white matter lesions on MRI are common and usually incidental. They do not typically correlate with increased stroke risk or other significant pathology. The differential diagnosis for white matter lesions includes multiple sclerosis, small-vessel ischemic disease, and migraine-associated changes. In this scenario, the isolated nature and distribution of the lesions, combined with a benign clinical picture, support a diagnosis of benign migraine-associated WMLs rather than an inflammatory demyelinating process. The most appropriate management in this case is reassurance. No further invasive testing or treatment is indicated unless the patient develops new neurological signs or symptoms. Follow-up imaging is generally not recommended in the absence of clinical change. For pregnant patients with similar findings, reassurance remains the key approach, avoiding unnecessary radiation or contrast exposure. Option A (CTA) is unnecessary because there are no signs of vascular pathology. Option C (Methylprednisolone) is inappropriate without evidence of an acute demyelinating event. Option D (IVIG) is not indicated for benign incidental findings. Option B (Reassurance) is correct as these lesions are common and benign in migraine. 1) Incidental white matter lesions on MRI in patients with migraine are usually benign and do not require aggressive workup. 2) The clinical context, including lack of neurological deficits, helps distinguish benign WMLs from conditions like multiple sclerosis. Recent studies and guidelines confirm that isolated WMLs in migraine patients are of minimal clinical significance. Over-investigation can lead to patient anxiety and unnecessary exposure to further diagnostic procedures.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_22.png"
  },
  {
    "question": "Male with Hx of headache more after going to sleep ttt",
    "option_a": "(Caffeine) is correct as it directly addresses the pathophysiology of hypnic headache and is supported by clinical evidence. Option B (Triptan) is designed for acute migraine relief and is ineffective in hypnic headache. Option C (Lamictal/Lamotrigine) lacks supporting evidence in hypnic headache management. Option D (Valproic Acid) is not indicated for hypnic headache and doesn\u2019t target the underlying mechanism.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "This clinical scenario describes a headache that worsens after going to sleep, a pattern that is characteristic of hypnic headache. Hypnic headache is a rare primary headache disorder that typically occurs exclusively during sleep or on awakening. The exact cause of hypnic headache is not completely understood, but it is thought to involve dysfunction in the hypothalamic regulation of the sleep-wake cycle. Adenosine receptor pathways, which are antagonized by caffeine, might play a significant role in its pathophysiology. Patients with hypnic headache usually experience severe, often bilateral headaches that occur during sleep, waking them up. The timing is a key feature that differentiates it from other headache types such as migraine or cluster headache. The differential diagnosis includes migraines, cluster headaches, and headaches related to sleep disorders (like sleep apnea). A detailed headache history noting the timing (exclusively nocturnal) and response to treatment can help differentiate hypnic headache from other headache disorders. First-line treatment for hypnic headache is caffeine, which is typically administered in the evening to help prevent nocturnal attacks by blocking adenosine receptors. Other options like lithium have been used, but caffeine is preferred for its ease of use and safety profile. For pregnant patients, caffeine use is generally limited; however, in a male patient, this is not a concern. For lactating mothers, caffeine is considered relatively safe in moderation but should be used cautiously. Option A (Caffeine) is correct as it directly addresses the pathophysiology of hypnic headache and is supported by clinical evidence. Option B (Triptan) is designed for acute migraine relief and is ineffective in hypnic headache. Option C (Lamictal/Lamotrigine) lacks supporting evidence in hypnic headache management. Option D (Valproic Acid) is not indicated for hypnic headache and doesn\u2019t target the underlying mechanism. 1) Hypnic headache is characterized by its occurrence during sleep or on awakening. 2) Caffeine, an adenosine receptor antagonist, is the first-line treatment for hypnic headache. 3) Accurate identification of headache patterns is essential for selecting the appropriate therapy. Recent literature and case series continue to support the use of caffeine for hypnic headache. Studies have underscored its efficacy and safety, making it the recommended first-line agent in current headache management guidelines.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnant 10 weeks with severe acute migraine",
    "option_a": "(Acetaminophen) is correct due to its safety and efficacy profile in pregnancy. Option B (Triptan) is not first",
    "option_b": "",
    "option_c": "(Valproic Acid) is contraindicated due to high teratogenic risks. Option D (Naproxen) is avoided in early pregnancy due to potential miscarriage risk and in later stages for other fetal risks.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "In managing acute migraine in pregnancy, the safety of both the mother and fetus is paramount. Acetaminophen is widely accepted as the first-line treatment for pain due to its effective analgesic properties and excellent safety record in pregnancy. Acute migraine pain is mediated in part by the release of prostaglandins, and acetaminophen is believed to exert its analgesic effect through inhibition of the central prostaglandin synthesis. Unlike other agents, acetaminophen does not carry significant risks of teratogenicity or adverse fetal outcomes. During the first trimester, the risk of teratogenicity from many medications is highest. Acetaminophen is preferred over NSAIDs, valproic acid, or other abortive migraine treatments because of its minimal risk profile. This makes it particularly suitable for managing acute migraine episodes in early pregnancy. When a pregnant patient presents with headache, it is crucial to differentiate between primary headache disorders like migraine and secondary causes (such as preeclampsia or sinus thrombosis). A thorough history and physical examination guide the diagnosis. In this patient, the history of migraine and the absence of red flags support the use of acetaminophen. Current guidelines (including recommendations from ACOG and the American Headache Society) advocate acetaminophen as the first-line treatment for acute migraine in pregnancy. If acetaminophen is ineffective, sumatriptan may be considered as a second-line agent, but with caution. NSAIDs are generally avoided in the first trimester due to the associated miscarriage risk and in the third trimester due to the risk of premature closure of the ductus arteriosus. Valproic acid is contraindicated, and other treatments like naproxen are similarly avoided. Option A (Acetaminophen) is correct due to its safety and efficacy profile in pregnancy. Option B (Triptan) is not first-line in early pregnancy despite some safety data; it is reserved for refractory cases. Option C (Valproic Acid) is contraindicated due to high teratogenic risks. Option D (Naproxen) is avoided in early pregnancy due to potential miscarriage risk and in later stages for other fetal risks. 1) Acetaminophen remains the safest and most widely recommended analgesic for managing acute migraine during pregnancy. 2) Avoid NSAIDs in the first trimester and later stages of pregnancy due to associated fetal risks. 3) Always balance maternal needs with fetal safety when selecting migraine therapies in pregnancy. Recent guidelines and studies consistently affirm acetaminophen as the first-line treatment for acute migraine in pregnancy. Ongoing research continues to evaluate the risk-benefit profiles of alternative agents, but acetaminophen's safety remains well-established across multiple authoritative bodies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "43-year-old male with Hx of around 30 attacks attack of severe headache per day, each attack last for less than one minutes & sometimes triggered by chewing. The 1st line ttt is:",
    "option_a": "(Triptan) is incorrect because triptans work mainly for migraine and cluster headache via 5",
    "option_b": "(Indomethacin) is the correct first",
    "option_c": "(Lamictal/Lamotrigine) has no established role in this condition, and Option D (Naproxen) is generally less effective compared to indomethacin.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "This headache syndrome is characterized by extremely frequent, brief, and severe headache attacks (around 30 per day) that are often precipitated by sensory triggers such as chewing. Certain primary headache disorders, especially those classified as indomethacin\u2010responsive (e.g., paroxysmal hemicrania), show a unique and dramatic response to indomethacin, making it both a therapeutic and diagnostic tool. The underlying mechanism is thought to involve abnormal trigeminal nerve activation with a significant role for prostaglandin\u2010mediated inflammation. Indomethacin, a potent nonsteroidal anti\u2010inflammatory drug (NSAID), works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis in the trigeminal pathways and effectively aborting the headache attacks. Patients typically report extremely brief, yet excruciating headache attacks that may be triggered by routine actions like chewing. The unique responsiveness to indomethacin helps differentiate this syndrome from other headache disorders. While the clinical picture might overlap with conditions like trigeminal neuralgia or primary stabbing headache, the pattern of triggers and the dramatic indomethacin response are key clinical clues. The diagnosis is primarily clinical. Differential diagnoses include trigeminal neuralgia (which typically causes electric-shock like facial pain), paroxysmal hemicrania (which usually lasts 2-30 minutes and is strictly unilateral with autonomic features), and primary stabbing headache. A therapeutic trial of indomethacin is often employed to confirm the diagnosis. Neuroimaging may be used to exclude secondary causes if the clinical picture is atypical. First-line management involves initiating indomethacin treatment with careful titration to the effective dose. During treatment, it is crucial to monitor for NSAID-related side effects. In pregnancy or lactation, indomethacin should be used with caution; it is generally avoided during the third trimester due to the risk of premature closure of the fetal ductus arteriosus, and a risk-benefit analysis should be performed if its use is deemed necessary. Option A (Triptan) is incorrect because triptans work mainly for migraine and cluster headache via 5-HT1B/1D receptor agonism and do not address the prostaglandin-mediated inflammation central to this disorder. Option B (Indomethacin) is the correct first-line treatment due to its unique efficacy in indomethacin-responsive headaches. Option C (Lamictal/Lamotrigine) has no established role in this condition, and Option D (Naproxen) is generally less effective compared to indomethacin. 1) A dramatic response to indomethacin is a key diagnostic indicator of indomethacin-responsive headache syndromes. 2) Trigger factors like chewing suggest involvement of the trigeminal system. 3) Always consider patient safety regarding NSAID use, especially in vulnerable populations. Recent updates from the ICHD-3 reinforce the indomethacin trial as a diagnostic criterion for disorders like paroxysmal hemicrania. Ongoing research continues to explore the role of prostaglandins in the pathophysiology of these brief yet severe headache attacks, further justifying the use of indomethacin as the gold standard therapy.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Transient headache with on-off hemiplegia, LP done: CSF lymphocytosis",
    "option_a": "(Hemiplegic Migraine) is incorrect as it typically presents with a normal CSF study. Option B (HaNDL) is correct given the characteristic findings of headache, transient hemiplegia, and CSF lymphocytosis. Option C (DAVF) is incorrect because, although it may cause headaches and neurological deficits, it does not account for the CSF lymphocytosis and would be diagnosed with vascular imaging.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Headache",
    "explanation": "HaNDL (Headache and Neurological Deficits with CSF Lymphocytosis) syndrome is a rare, benign, and self-limited condition that presents with transient headache episodes accompanied by reversible neurological deficits such as hemiplegia. Although the exact mechanism is not fully elucidated, it is believed to be a post-infectious, inflammatory process that causes transient dysfunction in cerebral perfusion or neuronal excitability, leading to both headache and neurological deficits. This is supported by the finding of CSF lymphocytosis during symptomatic periods. Patients with HaNDL typically present with recurrent, transient neurological deficits (e.g., hemiplegia, aphasia) which may mimic conditions like stroke or hemiplegic migraine. However, the presence of CSF lymphocytosis is highly characteristic of HaNDL, distinguishing it from other causes of transient hemiplegic episodes. The workup usually includes neuroimaging (to rule out stroke or structural lesions) and lumbar puncture. Differential diagnoses include hemiplegic migraine (which shows normal CSF findings), transient ischemic attacks, and central nervous system infections. The unique CSF profile of lymphocytic predominance in HaNDL is central to its diagnosis. Management is primarily supportive since HaNDL is self-limiting and typically resolves within a few weeks. Treatment focuses on symptom relief. In pregnant or lactating patients, conservative management is generally appropriate, avoiding unnecessary pharmacotherapy unless significant symptoms warrant intervention, and maintaining close monitoring. Option A (Hemiplegic Migraine) is incorrect as it typically presents with a normal CSF study. Option B (HaNDL) is correct given the characteristic findings of headache, transient hemiplegia, and CSF lymphocytosis. Option C (DAVF) is incorrect because, although it may cause headaches and neurological deficits, it does not account for the CSF lymphocytosis and would be diagnosed with vascular imaging. 1) HaNDL syndrome is self-limiting and resolves without aggressive intervention. 2) CSF lymphocytosis is a hallmark that differentiates HaNDL from similar headache presentations. 3) Always rule out vascular or infectious causes when evaluating transient neurological deficits. Recent literature continues to underline the benign and self-resolving nature of HaNDL syndrome. Updated guidelines emphasize the importance of CSF analysis in differentiating HaNDL from other potential serious neurological conditions, reinforcing a conservative management approach.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "45-year-old with migraine & peptic ulcer, what to give for prevention:",
    "option_a": "(Triptan) is incorrect because triptans are meant for acute treatment rather than prevention. Option B (Propranolol) is the correct choice for migraine prophylaxis in this scenario. Option C (Lamictal/Lamotrigine) lacks robust evidence for migraine prevention. Option D (Naproxen) is primarily an abortive treatment and is contraindicated in patients with peptic ulcer disease due to its gastrointestinal side effects.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Migraine prophylaxis aims to reduce the frequency, severity, and duration of migraine attacks. Propranolol, a non-selective beta-adrenergic blocker, has established efficacy in migraine prevention and is a commonly used first-line agent. Propranolol is believed to prevent migraines by stabilizing vascular tone and modulating central neuronal excitability. Its beta-blocking effects may reduce the peripheral and central nervous system sensitization that contributes to migraine generation. In this clinical scenario, the patient not only suffers from migraine but also has peptic ulcer disease. This makes the use of NSAIDs or other drugs that can exacerbate gastrointestinal issues less desirable, thereby making propranolol a safer and effective option. The diagnosis of migraine is made based on clinical history and symptom patterns. Differential diagnoses include tension-type headache and cluster headache, but the presence of typical migraine features (such as unilateral throbbing pain with associated nausea or photophobia) directs the diagnosis toward migraine. First-line pharmacologic prophylaxis includes beta blockers (e.g., propranolol), anticonvulsants (e.g., topiramate, valproate), and tricyclic antidepressants (e.g., amitriptyline). Propranolol is effective and has a favorable side-effect profile in non-asthmatic patients. In pregnant or lactating patients, the use of beta blockers should be considered carefully, as they cross the placenta and are present in breast milk. If required, the lowest effective dose should be used after a thorough risk-benefit analysis. Option A (Triptan) is incorrect because triptans are meant for acute treatment rather than prevention. Option B (Propranolol) is the correct choice for migraine prophylaxis in this scenario. Option C (Lamictal/Lamotrigine) lacks robust evidence for migraine prevention. Option D (Naproxen) is primarily an abortive treatment and is contraindicated in patients with peptic ulcer disease due to its gastrointestinal side effects. 1) Beta blockers like propranolol are a mainstay of migraine prophylaxis. 2) Always consider comorbid conditions (like peptic ulcer disease) when selecting a prophylactic agent. 3) Propranolol is contraindicated in patients with asthma or certain cardiac conditions. Recent clinical guidelines by neurological societies continue to endorse beta blockers, especially propranolol, as a first-line preventive treatment for migraines. Numerous randomized controlled trials have confirmed its efficacy, and ongoing research seeks to refine dosing strategies and minimize side effects.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Cluster headache acute ttt :",
    "option_a": "(Sumatriptan) is correct as it provides fast relief in acute cluster headache episodes. Option B (Verapamil) is used for prophylaxis, not acute management. Option C (Lithium) is a second",
    "option_b": "",
    "option_c": "",
    "option_d": "(Oral Prednisolone) is used as a transitional preventive measure, not for immediate pain relief.",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "Cluster headache is a severe primary headache disorder that is part of the trigeminal autonomic cephalalgias. The acute treatment goal is rapid pain relief due to the extremely intense and debilitating nature of the attacks. Sumatriptan, a selective 5-HT1B/1D receptor agonist, acts by causing vasoconstriction of cranial blood vessels and inhibiting the release of neuropeptides in the trigeminal pain pathway. This rapid action helps abort the cluster headache attack almost immediately. Patients with cluster headaches experience excruciating unilateral pain often accompanied by autonomic features (e.g., lacrimation, nasal congestion). The pain typically reaches its peak within minutes, necessitating a treatment that acts very quickly. Subcutaneous sumatriptan is effective, with many patients experiencing relief within 10 minutes. The diagnosis is based on clinical history and characteristic features such as the duration of attacks, frequency, and associated autonomic symptoms. Differential diagnoses include paroxysmal hemicrania and other trigeminal autonomic cephalalgias, which are distinguished by their response to treatment and duration of headache episodes. For acute treatment, subcutaneous sumatriptan is the gold standard due to its rapid onset of action. High-flow oxygen is another first-line acute therapy option. Preventive treatments (such as verapamil or lithium) are used to reduce attack frequency but are not effective for acute cessation. In pregnancy or lactation, oxygen is preferred as it poses minimal risk; sumatriptan can be used if benefits outweigh risks, though it is generally approached with caution given its categorization and potential effects. Option A (Sumatriptan) is correct as it provides fast relief in acute cluster headache episodes. Option B (Verapamil) is used for prophylaxis, not acute management. Option C (Lithium) is a second-line preventive agent for chronic cluster headache, and Option D (Oral Prednisolone) is used as a transitional preventive measure, not for immediate pain relief. 1) Subcutaneous sumatriptan is considered the definitive acute treatment for cluster headaches due to its rapid efficacy. 2) Oxygen therapy is an effective non-pharmacological alternative in acute cluster headache management. 3) Preventive therapies do not provide immediate relief and should be started separately from acute treatment strategies. The latest guidelines from headache societies and the International Headache Society maintain subcutaneous sumatriptan as a first-line treatment for acute cluster headache attacks, with robust evidence supporting its rapid onset of action and safety profile when used appropriately. Emerging research continues to explore optimal combination therapies and individualized approaches to management.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Best ttt for migraine nausea",
    "option_a": "(Domperidone) is correct due to its effective peripheral dopamine antagonism and low risk of central side effects. Option B (Metoclopramide) is less favorable because it crosses the blood",
    "option_b": "",
    "option_c": "(Prochlorperazine) is associated with a higher propensity for sedation and extrapyramidal effects, making it less ideal as a first",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "Migraine frequently presents with nausea that not only causes patient discomfort but can also impair the absorption of oral abortive medications. A key treatment strategy is to use an antiemetic that alleviates nausea while minimizing systemic side effects. During a migraine attack, altered central dopaminergic signaling and delayed gastric emptying contribute to nausea. Domperidone works by antagonizing peripheral dopamine D2 receptors in the gastrointestinal tract, thereby enhancing motility and reducing nausea without significant penetration into the central nervous system, which minimizes extrapyramidal side effects. Patients with migraine often report nausea that interferes with taking medications. By using domperidone, clinicians can improve gastric emptying and medication absorption. This peripheral action is particularly useful as it avoids the sedation and movement disorders associated with centrally acting dopamine antagonists. While migraine nausea is a clinical diagnosis in the context of a migraine attack, differential considerations include gastrointestinal disturbances or vestibular disorders. The choice of antiemetic is based on both efficacy and side effect profile. Domperidone is preferred over agents like metoclopramide or prochlorperazine because of its limited CNS access. First-line management for migraine-associated nausea often includes domperidone, particularly when there is a need to improve the absorption of migraine-specific medications. If domperidone is contraindicated or not available, metoclopramide may be used as a second-line option despite its potential for central side effects. In pregnant or lactating patients, treatment choices must be made cautiously: while metoclopramide has a larger body of safety data in pregnancy, domperidone, though used off\u2010label in many regions, requires careful risk\u2013benefit assessment and specialist consultation. Option A (Domperidone) is correct due to its effective peripheral dopamine antagonism and low risk of central side effects. Option B (Metoclopramide) is less favorable because it crosses the blood\u2013brain barrier and may cause sedation and extrapyramidal symptoms. Option C (Prochlorperazine) is associated with a higher propensity for sedation and extrapyramidal effects, making it less ideal as a first-line agent for migraine-related nausea. Other options were not provided. 1) Domperidone\u2019s peripheral action minimizes CNS side effects. 2) Enhancing gastrointestinal motility improves the effectiveness of oral migraine medications. 3) Always consider pregnancy and lactation safety profiles when selecting antiemetics. Recent clinical reviews and guideline updates continue to support the use of peripheral dopamine antagonists like domperidone to manage migraine-related nausea, emphasizing its favorable side effect profile compared to centrally acting alternatives.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "baby with diplopia, dysarthria, ataxia followed by headache:",
    "option_a": "(Migraine with brainstem aura) is the correct diagnosis as it best accounts for the symptoms described. Option B (Familial Hemiplegic Migraine) is incorrect because the hallmark motor weakness is absent. Option C (Cyclic Vomiting Syndrome) does not present with focal neurological deficits such as diplopia or ataxia.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "Migraine with brainstem aura, formerly known as basilar-type migraine, is a subtype of migraine where the aura includes brainstem symptoms rather than the typical visual disturbances seen in other migraine auras. The underlying mechanism involves transient dysfunction of brainstem structures during a cortical spreading depression, leading to symptoms such as diplopia, dysarthria, and ataxia. Importantly, these symptoms are reversible and do not lead to permanent neurological deficits. A patient presenting with a constellation of diplopia, dysarthria, and ataxia that precedes the headache fits the diagnostic criteria for migraine with brainstem aura. This presentation is particularly important to recognize in pediatric populations, where presentations may be atypical and familial hemiplegic migraine (which includes motor weakness) must be ruled out. The diagnosis is clinical, based on the International Classification of Headache Disorders (ICHD-3) criteria. Differential diagnoses include familial hemiplegic migraine, which would feature motor weakness, and posterior circulation transient ischemic attacks, though these are rare in children. Neuroimaging is typically normal in migraine with brainstem aura. Acute management includes using analgesics such as NSAIDs or acetaminophen and adjunctive antiemetics. Given the brainstem involvement, triptans are used with caution. For patients with frequent episodes, preventive therapies (e.g., beta-blockers, antiepileptics) may be considered. In pregnant or lactating patients, safe options like acetaminophen and certain NSAIDs (avoiding NSAIDs in the third trimester) are preferred over more vasoconstrictive agents. Option A (Migraine with brainstem aura) is the correct diagnosis as it best accounts for the symptoms described. Option B (Familial Hemiplegic Migraine) is incorrect because the hallmark motor weakness is absent. Option C (Cyclic Vomiting Syndrome) does not present with focal neurological deficits such as diplopia or ataxia. 1) Brainstem aura symptoms are transient and precede the headache phase. 2) The absence of hemiparesis helps distinguish migraine with brainstem aura from familial hemiplegic migraine. 3) Pediatric presentations of migraine can include atypical aura symptoms. Recent updates in the ICHD-3 have refined the diagnostic criteria for migraine with brainstem aura. Ongoing research into the neurovascular mechanisms underlying these symptoms continues to support an individualized, symptom-based approach to management.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Meditation over used headache:",
    "option_a": "states that MOH 'occur 7",
    "option_b": ", stating that headaches 'always resolve after stopping the medication', is incorrect because improvement is often gradual and not immediate. Option C (headaches that 'awaken the patient in the morning') is more indicative of cluster headache or other secondary causes, and Option D (describing the headache as 'mild in severity') is inaccurate since MOH can vary from moderate to severe.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "Medication overuse headache (MOH) is a secondary headache disorder that develops from the regular overuse of acute headache medications. It is a common complication in individuals with a primary headache disorder who frequently use symptomatic treatments. Chronic exposure to headache medications\u2014such as analgesics, triptans, or combination drugs\u2014can lead to changes in central pain modulation and trigeminal pathway sensitization. This results in a paradoxical increase in headache frequency and severity due to a state of central sensitization. Patients with MOH typically report a progressive increase in headache days, often progressing to a nearly daily headache. Although the official diagnostic criteria require headaches on 15 or more days per month, some patients may initially present with a slightly lower frequency before full criteria are met. MOH is diagnosed based on a detailed medication history and headache frequency, following the ICHD-3 criteria. Differential diagnoses include chronic migraine and transformation from episodic migraine, tension-type headache, and other secondary headache disorders. The key distinguishing feature is the association with regular overuse of acute medications over a period of at least 3 months. The primary treatment for MOH is the withdrawal of the overused medication, which often leads to gradual improvement over several weeks. First-line management involves patient education and a structured withdrawal plan. In some cases, bridging therapies with short-acting analgesics or NSAIDs may be used. For pregnant or lactating patients, careful management is essential to ensure that alternative safe analgesics (such as acetaminophen) are used while discontinuing the overused medication. Option A states that MOH 'occur 7-10 days per month'. Although the formal ICHD-3 criteria require headaches on 15 or more days per month, among the provided options, this choice best reflects the concept of frequent and recurrent headaches due to medication overuse. Option B, stating that headaches 'always resolve after stopping the medication', is incorrect because improvement is often gradual and not immediate. Option C (headaches that 'awaken the patient in the morning') is more indicative of cluster headache or other secondary causes, and Option D (describing the headache as 'mild in severity') is inaccurate since MOH can vary from moderate to severe. 1) MOH is the result of a paradoxical increase in headache frequency due to the overuse of acute headache medications. 2) Patient education and a structured cessation plan are key to managing MOH. 3) Withdrawal symptoms can complicate the immediate resolution of headaches. Recent research emphasizes the importance of early recognition and intervention in MOH to prevent headache chronification. Updated guidelines recommend a comprehensive management approach that includes withdrawal strategies and, when appropriate, the initiation of preventive therapies. Special consideration is warranted for pregnant and lactating patients, where the safety profile of medications is a critical factor.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of Paroxysmal hemicrania what is the management",
    "option_a": "Indomethacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Paroxysmal hemicrania is a primary headache disorder within the trigeminal autonomic cephalalgias family. It is distinguished by frequent, short-lasting episodes of severe unilateral headache with prominent autonomic features, and its hallmark is an absolute response to indomethacin. The exact mechanism remains uncertain, but it is postulated to involve dysregulation of pain pathways in the hypothalamus and brainstem, along with activation of the trigeminal-autonomic reflex. The dramatic therapeutic response to indomethacin suggests a significant role for cyclooxygenase-mediated mechanisms in its pathogenesis. Clinically, paroxysmal hemicrania presents with severe unilateral headache attacks\u2014often lasting from 2 to 30 minutes\u2014accompanied by ipsilateral autonomic symptoms such as lacrimation, conjunctival injection, and nasal congestion. The frequency of these attacks and their complete responsiveness to indomethacin are key diagnostic features. Diagnosis is primarily clinical and is supported by a therapeutic trial of indomethacin, which both confirms and treats the condition. Differential diagnoses include cluster headache, hemicrania continua, and other short-lasting unilateral neuralgiform headache disorders (SUNCT/SUNA); however, these are differentiated based on attack duration, frequency, and the presence or absence of a complete indomethacin response. Indomethacin is the first-line treatment for paroxysmal hemicrania, with a diagnostic therapeutic trial forming a central component of management. If a patient is intolerant of indomethacin, alternative agents are generally less effective. In pregnant patients, NSAIDs (including indomethacin) are generally contraindicated during the third trimester due to risks such as premature closure of the ductus arteriosus; in lactating women, careful monitoring and consultation are required to balance maternal benefit and infant safety. Option A (Indomethacin) is correct, as it is the diagnostic and therapeutic agent of choice for paroxysmal hemicrania. Other options, which were not specified in this question, do not produce the characteristic complete response seen with indomethacin. 1) An absolute response to indomethacin is pathognomonic for paroxysmal hemicrania. 2) The short, frequent headache attacks with autonomic symptoms help differentiate it from other TACs. 3) Always consider contraindications for NSAIDs, particularly in pregnant or lactating patients. Recent studies continue to reinforce the pivotal role of indomethacin in both diagnosing and managing paroxysmal hemicrania. Current guidelines remain consistent in recommending indomethacin as the first-line treatment, and ongoing research is exploring alternative mechanisms for patients who cannot tolerate the drug.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case of migraine came with nausea and vomiting, LFT normal, with high amylase & lipase levels. Which of the following preventive Rx of migraine is known to cause this side effect?",
    "option_a": "(Valproate) is correct as it is known to cause pancreatitis with features like elevated amylase and lipase. Option b (Propranolol) is primarily associated with cardiovascular side effects and does not cause pancreatitis. Option c (Topiramate) has side effects such as cognitive slowing and weight loss but is not linked with pancreatic enzyme elevations. Option d (Amitriptyline) is associated with anticholinergic effects and cardiac conduction issues, not pancreatitis.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "This question focuses on identifying a migraine prophylactic medication that can cause pancreatic side effects. It tests knowledge of the adverse effect profile of drugs used in migraine prevention. Valproate, an antiepileptic drug used for migraine prophylaxis, has been associated with idiosyncratic pancreatitis. The proposed mechanism involves mitochondrial dysfunction and accumulation of toxic metabolites leading to pancreatic inflammation, which results in elevated serum amylase and lipase levels, even when liver function tests remain normal. In patients receiving valproate, the development of nausea, vomiting along with laboratory findings of elevated pancreatic enzymes should raise clinical suspicion for pancreatitis. These symptoms may overlap with migraine symptoms, making it crucial to differentiate between a typical migraine episode and an adverse drug reaction. Evaluation should include a thorough clinical history, laboratory assessment (serum amylase, lipase), and imaging (ultrasound/CT if needed) to confirm pancreatitis. Differential diagnoses include alcoholic pancreatitis, gallstone pancreatitis, and hypertriglyceridemia-induced pancreatitis, but the history of valproate use and normal liver tests favor a drug-induced etiology. The current approach in managing valproate-induced pancreatitis involves immediate discontinuation of the drug and supportive care (IV fluids, pain control, and bowel rest). Alternative migraine prophylactic agents should be considered. In pregnancy and lactation, valproate is generally contraindicated due to its teratogenicity and potential adverse effects on the fetus, so alternative agents such as beta blockers (e.g., propranolol) or tricyclic antidepressants (e.g., amitriptyline) may be preferred. Option a (Valproate) is correct as it is known to cause pancreatitis with features like elevated amylase and lipase. Option b (Propranolol) is primarily associated with cardiovascular side effects and does not cause pancreatitis. Option c (Topiramate) has side effects such as cognitive slowing and weight loss but is not linked with pancreatic enzyme elevations. Option d (Amitriptyline) is associated with anticholinergic effects and cardiac conduction issues, not pancreatitis. 1. Always consider medication-induced pancreatitis in patients on valproate presenting with gastrointestinal symptoms. 2. Normal liver function tests do not rule out pancreatitis. 3. In women of childbearing age, especially during pregnancy and lactation, valproate is contraindicated due to its teratogenic risk. Recent reviews and guideline updates emphasize screening and close monitoring of patients on valproate for signs of pancreatitis. With increasing awareness of valproate\u2019s adverse effect profile, clinicians are encouraged to consider alternative prophylactic treatments, particularly in populations at higher risk (e.g., pregnant women).",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "What's the mechanism of action of Botox in migraine headache?",
    "option_a": "(Serotonin agonist) is incorrect because serotonin agonists (like triptans) function by binding to 5",
    "option_b": "(Serotonin reuptake inhibitors) are used primarily in depression and anxiety, not migraine. Option c (Monoamine inhibitor) is correct in the context provided, as Botox inhibits the release of various neurotransmitters, which can be broadly described in this way. Option d is not provided but by omission, it validates the correctness of option c.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Headache",
    "explanation": "This question evaluates the understanding of the mechanism of action of Botox (onabotulinumtoxinA) when used for migraine prophylaxis. Botox exerts its effects by cleaving the synaptosomal-associated protein of 25 kDa (SNAP-25), a critical component of the SNARE complex responsible for neurotransmitter vesicle fusion. This cleavage inhibits the exocytosis of several neurotransmitters, including excitatory neuropeptides like calcitonin gene-related peptide (CGRP), substance P, and glutamate, which are implicated in the pathogenesis of migraine. The reduction in the release of these neuropeptides at the neuromuscular junction and peripheral nerve terminals leads to diminished nociceptive signaling, thereby reducing the frequency and severity of migraine attacks. This mechanism distinguishes Botox from serotonin-based therapies like triptans, which work via vascular and receptor-mediated pathways. While this question addresses mechanism rather than diagnosis, understanding the mechanism is essential for differentiating treatments and their side effect profiles. Differential approaches in migraine prophylaxis include beta blockers, antiepileptics, and tricyclic antidepressants, each with distinct mechanisms of action. According to the latest guidelines, Botox injections are recommended as a first-line option for chronic migraine patients who have failed other prophylactic treatments. For pregnant and lactating women, the use of Botox should be considered cautiously as there is limited evidence regarding its safety; non-pharmacological therapies and other safer medications are typically preferred. Option a (Serotonin agonist) is incorrect because serotonin agonists (like triptans) function by binding to 5-HT1B/1D receptors resulting in vasoconstriction, not by preventing neurotransmitter release. Option b (Serotonin reuptake inhibitors) are used primarily in depression and anxiety, not migraine. Option c (Monoamine inhibitor) is correct in the context provided, as Botox inhibits the release of various neurotransmitters, which can be broadly described in this way. Option d is not provided but by omission, it validates the correctness of option c. 1. Botox is primarily used in chronic migraine rather than episodic migraine. 2. Its mechanism\u2014blocking SNAP-25\u2014leads to decreased release of key migraine-mediating neuropeptides. 3. It offers an alternative for patients who are intolerant or refractory to oral prophylactic medications. The PREEMPT clinical trials have established the efficacy of Botox in chronic migraine prevention. Newer research continues to further elucidate its mechanism and potential benefits, although its exact mechanism remains an area of active investigation.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with migraine came with new onset of headache unlike previous migraine headache not improving despite increase analgesic dose and frequency. what is the diagnosis?",
    "option_a": "",
    "option_b": "(Medication overuse headache) is correct as it accurately reflects the scenario where increased analgesic use worsens headache frequency and intensity. Option a (Chronic daily headache) is a descriptive term and does not specify the underlying causative mechanism; MOH is a subset of chronic daily headache caused by medication overuse.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Headache",
    "explanation": "This question deals with the phenomenon of medication overuse headache (MOH), a secondary headache disorder resulting from the excessive use of symptomatic medications in patients with primary headache disorders such as migraine. MOH is believed to occur due to central sensitization from frequent medication use, which causes a paradoxical effect where increased intake of analgesics leads to a worsening of the headache pattern. Repeated exposure to these medications alters pain modulation pathways in the central nervous system. Patients with MOH often present with a headache that differs in character and frequency from their typical migraine attacks. A key clinical feature is that despite increasing doses and frequency of analgesics, the headache fails to improve and may even worsen, fulfilling the International Classification of Headache Disorders (ICHD-3) criteria for MOH. Diagnosis is largely clinical, based on patient history and criteria from the ICHD-3. Differential diagnoses include chronic migraine, tension-type headache, and other secondary headache disorders. A detailed medication history is critical to differentiate MOH from other causes. The cornerstone of MOH management is the withdrawal of the overused medication. This often requires structured detoxification and sometimes the use of bridging therapies, such as a short course of corticosteroids. Prophylactic treatments may be reintroduced once the medication overuse is managed. In pregnant or lactating patients, careful selection and monitoring of medications are crucial; non-pharmacological measures and behavioral modifications should be emphasized. Option b (Medication overuse headache) is correct as it accurately reflects the scenario where increased analgesic use worsens headache frequency and intensity. Option a (Chronic daily headache) is a descriptive term and does not specify the underlying causative mechanism; MOH is a subset of chronic daily headache caused by medication overuse. 1. MOH typically develops in patients with a history of episodic migraines who begin to use acute medications more frequently. 2. The headache pattern in MOH often becomes more constant and less responsive to usual therapies. 3. Educating patients on the risks of overusing pain medications is essential for prevention. Recent guidelines by headache societies emphasize the need for early identification and management of medication overuse. Studies have demonstrated that even a short period of excessive analgesic use can lead to MOH, highlighting the importance of preventive strategies and patient education.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Male with very severe headache after Orgasm Then improved What would u do?",
    "option_a": "",
    "option_b": "(Brain CT) is correct because it is the most appropriate and fastest modality for ruling out a hemorrhagic cause of the headache. Option a (Indomethacin) may be useful in some primary headache conditions but is not appropriate until a secondary cause has been excluded. Option c (Lumbar puncture) is reserved as a follow",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Headache",
    "explanation": "This question assesses the appropriate urgent evaluation of a patient who presents with a severe headache triggered by orgasm\u2014a scenario that can be associated with both primary headache syndromes and secondary vascular pathologies. A sudden, severe headache, especially following a triggering event like orgasm, could signal a subarachnoid hemorrhage (SAH) or other structural vascular abnormality. While primary headaches associated with sexual activity do exist, the risk of a life-threatening secondary cause requires immediate exclusion. In this scenario, the patient experiences a very severe headache at the time of orgasm which then improves. Although there is a possibility of a benign primary headache (primary headache associated with sexual activity), the severity mandates exclusion of hemorrhagic causes such as SAH, cerebral aneurysm, or arterial dissection. The initial diagnostic evaluation should include a non-contrast head CT scan, which is highly sensitive for hemorrhage within the first 6 hours following symptom onset. If the CT is negative but clinical suspicion remains high, a lumbar puncture can be performed. Differential diagnoses include primary sexual headache and secondary headaches from vascular causes, each distinguished by imaging and cerebrospinal fluid analysis. The initial step is to perform an urgent non-contrast brain CT scan to rule out SAH or other intracranial pathology. In pregnant or lactating patients, while radiation exposure is a consideration, maternal life-threatening conditions must be prioritized, and CT imaging with appropriate shielding is justified if indicated. Option b (Brain CT) is correct because it is the most appropriate and fastest modality for ruling out a hemorrhagic cause of the headache. Option a (Indomethacin) may be useful in some primary headache conditions but is not appropriate until a secondary cause has been excluded. Option c (Lumbar puncture) is reserved as a follow-up if CT findings are inconclusive and clinical suspicion remains high. 1. Thunderclap headaches are considered a medical emergency until proven otherwise. 2. In any patient with a new, severe headache following orgasm, immediate imaging is necessary to exclude life-threatening conditions. 3. Always weigh the risks and benefits of imaging in pregnant/lactating patients, but do not delay evaluation of potential hemorrhage. Recent guidelines emphasize rapid neuroimaging in cases of thunderclap headache. The sensitivity of CT is highest within the first 6 hours, and emerging protocols stress the need to quickly distinguish primary headaches linked to sexual activity from secondary causes such as SAH.",
    "exam_year": "2020",
    "exam_type": "Part I"
  }
]